Clinical Trials Logo

Hematologic Malignancy clinical trials

View clinical trials related to Hematologic Malignancy.

Filter by:

NCT ID: NCT03890614 Recruiting - Clinical trials for Hematologic Malignancy

Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity

Organoid
Start date: May 16, 2019
Phase:
Study type: Observational

The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed hematologic malignancy and potentially other cancers.

NCT ID: NCT03823651 Active, not recruiting - Clinical trials for Hematologic Malignancy

A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP)

Start date: June 27, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the feasibility and outcomes of a research pre- and peri-transplant optimization program (R-PPOP) to improve multiple domains of health including physical function, cognitive function, mental health, and diet and nutrition for patients planning to undergo or undergoing hematopoietic stem cell transplantation (HCT).

NCT ID: NCT03800758 Completed - Clinical trials for Hematologic Malignancy

Expressive Helping for Stem Cell Transplant Patients

Start date: March 6, 2019
Phase: Phase 3
Study type: Interventional

The Writing for Insight, Strength, and Ease (WISE) Study is a multisite Randomized Controlled Trial (RCT) testing the efficacy of the Expressive Helping (EH) intervention among adults receiving hematopoietic stem cell transplantation.

NCT ID: NCT03795779 Recruiting - Clinical trials for Acute Myeloid Leukemia

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Start date: March 1, 2018
Phase: Early Phase 1
Study type: Interventional

Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CLL1-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.

NCT ID: NCT03727009 Terminated - Clinical trials for Hematologic Malignancy

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies

Start date: December 7, 2018
Phase:
Study type: Observational

The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.

NCT ID: NCT03717480 Terminated - Clinical trials for Hematologic Malignancy

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

Start date: January 21, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying the removal of a subset of white blood cells (called alpha/beta T cells) from the donor product using a cell separation device before the product is transplanted into the participant. The device used to remove the α/βT cells in this study is: -CliniMACS® TCR α/β Reagent System

NCT ID: NCT03699631 Completed - Clinical trials for Hematologic Malignancy

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

Start date: November 6, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II open-label trial designed to evaluate the efficacy of tocilizumab in improving GVHD-free/relapse-free survival (GRFS) after allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.

NCT ID: NCT03673631 Recruiting - Cancer Clinical Trials

Oxygenation Methods and Non-invasive Ventilation in Patients With Acute Respiratory Failure and a do Not Intubate Order

OXYPAL
Start date: August 7, 2018
Phase:
Study type: Observational

ICU care of patients considered "palliative" but without contraindications to admission to intensive care, for whom a do-not intubate order decision was made upon admission represents a particular target for non-invasive oxygenation techniques. The benefits of non invasive ventilation (NIV) in this population are debated especially in cancer patients. The more recently used nasal humidified high flux canula oxygenation (HFNC) therapy may have benefits over NIV in these patients. It is supposed to have better tolerance and could allow better compliance and thus higher efficiency. These potential benefits are major for such a population for which tolerance and symptomatic relief are priority goals

NCT ID: NCT03654404 Completed - Clinical trials for Hematologic Malignancy

A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients

Start date: September 11, 2018
Phase: N/A
Study type: Interventional

The goal of this research study is to find out if a novel phone-based positive psychology intervention that focuses on improving health behaviors and positive emotions can help improve mood, health related quality of life, and overall function in patients who have just undergone hematopoietic stem cell transplantation as part of blood cancer treatment.

NCT ID: NCT03555955 Completed - Clinical trials for Acute Myeloid Leukemia

A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Start date: November 20, 2018
Phase: Phase 1
Study type: Interventional

This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.